PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 51712

[Patho-physiological aspects in csf proteins (author's transl)].

H Glasner
View original source ↗Export metadata ↓

Abstract

Electrophoresis and immunoelectrophoresis of cerebrospinal fluid of 201 patients with inflammatory CNS diseases revealed that over a total protein value from 0 to greater than 1, 2 g/1 there was merely a decrease in pre-albumins and a difference in the gamma-globulins as a pointer to immune reactions. Comparison with the absolute values indicated an increase of all fractions in inflammatory and non inflammatory diseases caused by impairment of the blood-CSF barrier. Again there was evidence of immune reaction in the gamma-globulin range. Impairment in the blood-CSF barrier was demonstrated by an increased concentration of IgG, IgA and IgM. An immune reaction was revealed by higher IgG values.

Explore related subjects

Blood-Brain BarrierCentral Nervous System DiseasesCerebrospinal Fluid ProteinsElectrophoresisHumansImmunoelectrophoresisImmunoglobulin AImmunoglobulin GImmunoglobulin MImmunoglobulinsPrealbumingamma-GlobulinsComparative StudyEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Glasner. 1975-08-08. [Patho-physiological aspects in csf proteins (author's transl)].. https://doi.org/10.1055/s-0028-1106434

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2025

Protective effects of liver-derived apolipoprotein A1 against heat stress-induced hypothalamic lipid metabolism and blood-brain barrier integrity.

Heat stress (HS), a prevalent occupational and environmental hazard, has increasingly been recognized as a major contributor to multiple physiological disorders. The hypothalamus, a key regulator of thermoregulation and endocrine signaling, is especially susceptible to metabolic and inflammatory disturbances induced by HS. This study investigates the interplay among lipid metabolism, blood-brain barrier (BBB) integrity, and neuroinflammation in the hypothalamus under HS conditions, with a specific focus on apolipoprotein A1 (APOA1) as a potential protective factor. To achieve this, we integrated proteomic and lipidomic analyses with experimental validation in porcine and murine models. Proteomic analysis identified 266 differentially expressed proteins (DEPs) in the hypothalamus following HS, with significant enrichment in lipid metabolism pathways-especially glycerophospholipid (GP) metabolism-in which APOA1 displayed a marked increase. Lipidomic profiling further revealed HS-induced disruptions in phosphatidylcholine (PC), phosphatidylethanolamine (PE), and cardiolipin (CL) metabolism. Additionally, blood-brain barrier integrity was compromised, as evidenced by increased perivascular IgG extravasation, reduced pericyte coverage, and decreased expression of tight junction proteins ZO-1 and Occludin. HS also triggered pronounced neuroinflammation, characterized by elevated levels of iNOS, GFAP, and pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6). Notably, administration of D-4F, an APOA1 mimetic peptide, alleviated blood-brain barrier damage, reduced neuroinflammation, and preserved synaptic integrity, thereby suggesting a neuroprotective role for APOA1 in HS-induced hypothalamic dysfunction. These findings underscore the critical role of lipid metabolism in maintaining hypothalamic homeostasis under HS conditions and position APOA1 as a key regulator with potential therapeutic implications for mitigating HS-related neuroinflammatory and metabolic disturbances.

Blood-Brain Barrier↗
PubMed2007

Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: looking for the grail.

Most therapeutic drugs distribute to the whole body, which results in general toxicity and poor acceptance of the treatments by patients. The targeted delivery of chemotherapeutics to defined cells, either stromal or cancer cells in cancer lesions, or defined inflammatory cells in immunological disorders, is one of the main challenges and a very active field of research in the development of treatment strategies to minimize side-effects of drugs. Disease-associated cells express molecules, including proteases, receptors, or adhesion molecules, that are different or differently expressed than their normal counterparts. Therefore one goal in the field of targeted therapies is to develop chemically derivatized drugs or drug vectors able to target defined cells via specific recognition mechanisms and also able to overcome biological barriers. This article will review the approaches which have been explored to achieve these goals and will discuss in more detail three examples (i) the use of nanostructures to take advantage of increased vascular permeability in some human diseases, (ii) the targeting of therapeutic drugs to an organ, the brain, protected against foreign molecules by the blood-brain barrier, and (iii) the use of the folate receptor to target either tumor cells or activated macrophages.

Blood-Brain Barrier↗